Companies ›Healthcare ›056090.KQ

056090.KQ — KOSDAQ Medical Equipment, Supplies & Distribution

CG MedTech Co Ltd

$1 700,00

Open in Charts → Attach watcher ⌖

— —

KRW

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

175,5B KRW

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

CG MedTech Co Ltd designs, develops, and distributes medical equipment and supplies, primarily serving the healthcare sector.

Business. CG MedTech Co Ltd (056090.KQ) is a healthcare services and equipment company operating in the medical equipment, supplies, and distribution industry. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryMedical Equipment, Supplies & Distribution

ActivityHealthcare Services & Equipment

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 056090.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 056090.KQ. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

CG MedTech Co Ltd (056090.KQ) is a healthcare services and equipment company operating in the medical equipment, supplies, and distribution industry. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryMedical Equipment, Supplies & Distribution

ActivityHealthcare Services & Equipment

AI synthesis

GENERATED

CG MedTech has a market capitalization of 169,757,855,184 USD, with a market price of 1,644 USD per share. The company has 103,259,036 basic and diluted shares outstanding, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company's profitability is reflected in its last actual EPS of 63.00 USD and EBIT of 9,100,000,000 USD, according to analyst estimates. These figures suggest a strong performance relative to industry standards, though direct comparisons to cohort medians are not available in the current dataset.

CG MedTech's revenue is concentrated in the healthcare services and equipment segment, with no disclosed geographic breakdown. The company's primary exposure is to the domestic market, as no international revenue segments are reported in the available data.

Looking ahead, the company is expected to see a significant increase in revenue, with a mean estimate of 69,450,000,000 USD compared to the last actual revenue of 47,234,950,000 USD. This represents a growth trajectory of approximately 47% year-over-year.

The company's risk profile is characterized by low dilution potential and an inability to assess liquidity risk. No recent filings or transcripts indicate significant operational or financial risks, and there is no evidence of dilution pressure from recent issuance or shelf registration.

No recent events, such as filings or transcripts, have been reported in the available data to indicate significant changes in the company's operations or financial status.

Key takeaways

CG MedTech has a strong market position in the medical equipment and supplies industry.
The company is expected to experience significant revenue growth in the upcoming period.
There is no immediate dilution pressure from share issuance.
Liquidity risk could not be assessed due to the lack of balance-sheet inputs.
The company's revenue is concentrated in the healthcare services and equipment segment.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$1 700,00

Market cap

$169.76B

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

72,35

Predicted surprise

0,00

Beat probability

45 %

Analysts

—

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-12 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	72,35
Revenue	—no estimate	—no estimate	69,5B
Operating income	—no estimate	—no estimate	9,1B

Full-year consensus mean (period as reported by source). Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Operating income · consensus9,1B

EPS surprise

−12,9 %

reported vs consensus · miss

Revenue surprise

−32,0 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

CG MedTech Co Ltd Market data — financials · 2026-05-26
CG MedTech Co Ltd Market data — analyst estimates · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

056090.KQCanonical

KOSDAQ · KRW

Intel & risk

PredictorBeat prob45 %Surprise0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-03-19 13:14 UTCEARNINGSQuarterly results — Q4 2025

2026-03-19 13:14 UTCEARNINGSAnnual results — FY 2026

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread